Ausgabe 6/2015
Inhalt (7 Artikel)
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
Daphne Robakis, Stanley Fahn
Targeting CGRP: A New Era for Migraine Treatment
Stephanie Wrobel Goldberg, Stephen David Silberstein
Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
Lawrence K. Fung, Antonio Y. Hardan
Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations
Caroline A. Arout, Ellen Edens, Ismene L. Petrakis, Mehmet Sofuoglu
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Andreas Soejitno, Anastasia Tjan, Thomas Eko Purwata
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
Barbara H. Johnson, Machaon M. Bonafede, Crystal Watson
Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome
James E. Frampton